Letteratura

• Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007;298:655–69.
• Calabrese LH, Molloy ES, Duna G. Antineutrophil cytoplasmic antibody-associated vasculitis. In: Firestein GS, Kelley WN, eds. Kelley's Textbook of Rheumatology. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2009.
• Chen M, Kallenberg CG. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010;9:A293–8.
• Drooger JC, Dees A, Swaak AJ. ANCA-positive patients: The influence of PR3 and MPO antibodies on survival rate and the association with clinical and laboratory characteristics. Open Rheumatol J 2009;3:14–7.
• Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol 2010;21:745–52.
• Falk RJ, King TE, Stone JH. Clinical manifestations and diagnosis of Wegener’s granulomatosis and microscopic polyangiitis: UpToDate; 2010.
• Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: summary. Arthritis Rheum 1990;33:1135–6.
• Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011;50:1916–20.
• Gomez-Puerta JA, Bosch X. Antineutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am J Pathol 2009;175:1790–1798.
• Gómez-Puerta JA, Hernandez-Rodriguez J, Lopez-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest. 2009;136:1101–11.
• Guillevin L. Polyarteritis nodosa and microscopic polyangiitis. In: Ball GV, Bridges SL, eds. Vasculitis. Oxford: Oxford University Press, 2002:300–20.
• Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int
• Hamour S, Salama AD, Pusey CD. Management of ANCA-associated vasculitis: current trends and future prospects. Ther Clin Risk Manag 2010;6:253–64.
• Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605–17.
• Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–98.
• Hoffman GS, Langford CA. Are there different forms of life in the antineutrophil cytoplasmic antibody universe? Ann Intern Med 2005;143:683–5.
• Holle JU, Laudien M, Gross WL. Clinical manifestations and treatment of Wegener’s Granulomatosis. Rheum Dis Clin North Am 2010;36:507–26.
• Hunder GG. Classification of and approach to the vasculitides in adults: In: Stone JH (ed). UpToDate. Waltham, MA: UpToDate; 2010.
• Jayne D, Rasmussen N, Andrassy K, Bacon P, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis,1994.
• Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiologic potential. Kidney Int 1994;46:1–15.
• Kallenberg CG. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep 2010;12:399–405.
• Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009;123:1226–36.
• King TE. Clinical features and diagnosis of Churg-Strauss syndrome (allergic granulomatosis and angiitis): UpToDate;2010a.
• King TE. Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis): UpToDate;2010b.Rheum 1994;37:187–92.1998;53:743–53.
• Lamprecht P, Gross WL. Wegener’s granulomatosis. Herz 2004;29:47–56.
• Lane SE, Watts RA, Scott DGI. Primary systemic vasculitis: clinical features and mortality. Q J Med 2005;98:97–112.
• Langford CA. Vasculitis. J Allergy Clin Immunol 2010;125(2 Suppl. 2):S216–S225.
• Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984;63:65–81.
• Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101–7.
• Lightfoot RW, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088–94.
• Linder R, Orth I, Hagen EC, et al. Differentiation between Wegener's granulomatosis and microscopic polyangiitis by an artificial neural network and by traditional methods. J Rheumatol 2011;38:1039–47.
• Lionaki S, Jennette JC, Falk RJ. Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Semin Immunopathol 2007;29:459–74.
• Luqmani RA, Exley AR, Kitas GD, et al. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423–46.
• Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094–100.
• Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004–10.
• Mukhtyar C, Guillevin L, Cid MC, et al.; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310–7
• Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010;36:447–61.
• Popa ER, Stegeman CA, Bos NA, et al. Differential band T-cell activation in Wegener’s granulomatosis. J Allergy Clin Immunol 1999;103:885–94.
• Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000;57:846–62.
• Specks U, Wheatley CL, McDonald TJ, Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. Mayo Clin Proc 1989;64:28–36.
• Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis – incidence and risk factors. Rheumatology (Oxford) 2008;47:530–4. 
• Stone J, Merkel P, Seo P, et al. Long-term results of the RAVE Trial: Which disease subsets are at greatest risk for disease flare? Presented at the American College of Rheumatology (ACR) congress, 2011.
• Stone JH. The classification and epidemiology of systemic vasculitis. In: Firestein GS, Kelley WN, eds. Kelley's textbook of rheumatology. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2009. Stone JH.
• The antineutrophil cytoplasmic antibody-associated vasculitides: Wegener’s granulomatosis, microscopic polyangiitis, and the Churg-Strauss syndrome. In: Klippel JH, Stone JH, Crofford LJ, White PH, eds. Primer on the Rheumatic Diseases. 13th ed. New York, NY: Springer; 2008.
• Suppiah R, Robson J, Luqmani R. Outcome Measures in ANCA-associated Vasculitis. Rheum Dis Clin North Am 2010;36:587–607.
• Tarabishy AB, Schulte M, Papaliodis GN, Hoffman GS. Wegener's granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv Ophthalmol 2010;55:429–44.
• Tsiveriotis K, Tsirogianni A, Pipi E, et al. Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected Greek patients. Autoimmune Dis  2011;2011:626495.
• Villiger PM, Guillevin L. Microscopic polyangiitis: Clinical presentation. Autoimmun Rev 2010;9:812–9.
• Voswinkel J, Müller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener’s granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005;1051:12–9.
• Voswinkel J, Müller A, Kraemer JA, et al. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006;65:859–64.
• Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–7.
• Watts RA, Lane SE, Scott DG et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001;60:1156–7.
• Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842–52.
• Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford). 2002;41:481–3.